Medpace(NASDAQ) MEDP

Medpace Holdings, Inc. helps drug and medical device companies run clinical trials. It manages the complex research needed to test if new medicines are safe. These services help bring new treatments to patients faster.

From the Lab to the Market

• Phase I-IV Clinical Development: Full-service management of trials from initial human testing through post-market safety monitoring.
• Central Laboratory Services: Specialized testing and bioanalytical services that support global clinical research programs.
• Regulatory and Data Management: Navigating government approval processes and handling the large amounts of data generated during trials.
• Therapeutic Expertise: Specialized research focus in areas like cancer, heart disease, metabolic disorders, and brain health.

Growing the Global Workforce

• Expanded the global workforce to approximately 6,500 employees across 46 countries as of June 30, 2026.
• Increased net new business awards to $1.41 billion for the six-month period ended June 30, 2026.
• Allocated $294.7 million for the repurchase of 705,616 shares during the first half of 2026.
• Increased capital spending to 2.2% of revenue for the six months ended June 30, 2026.

Scientific Expertise and Global Scale

Medpace uses a disciplined, full-service operating model that integrates scientific expertise with global project management. This approach allows the company to serve small- and mid-sized biopharmaceutical firms that require high-quality results across diverse patient populations.

Tracking Financial Progress

• Total revenue rose 21.7% to $1.41 billion for the six months ended June 30, 2026.
• Net income was $245.2 million for the six-month period ended June 30, 2026.
• Total backlog grew to $3.01 billion as of June 30, 2026, a 4.9% increase year over year.
• Cash and cash equivalents rose to $502.7 million by the end of June 2026.
• The company reported zero indebtedness under its $10 million credit facility as of June 30, 2026.

Bottom Line

Medpace has established itself as a focused clinical research partner by combining therapeutic depth with a global reach. Its growth is driven by a steady increase in new business awards and a solid backlog of long-term research projects.